ABSTRACT
Recognizing the explosive growth in information on intravenous immunoglobulins (IVIGs), this exhaustive single-source volume surveys all available literature on the employment of IVIG preparations in clinical practice from pharmacoeconomics and pharmacokinetics to prophylaxis and management of infectious and autoimmune diseases.
TABLE OF CONTENTS
chapter |5 pages
< .01) cumulative decrease of CIC occurred (9,10,14). Similarly,
< unity) are characteristic for B-cell
chapter |3 pages
of the patients surviving, including six of the seven with bacteremia. This benefit was
+ children. One child, who shed RSV for 199 days, + children must be recognized and assessed during therapy.
